The data collected for this review were derived from “Pubmed”, “Scopus”, and regulatory databases by searching the following keywords: inflammatory bowel diseases, traditional treatments, monoclonal antibodies, drug delivery systems, aminosalicylates, corticosteroids, immunomodulators, Tumor Necrosis Factor-α (TNF-α) blockers, integrin blockers, interleukin blockers, infliximab, adalimumab, golimumab, certolizumab pegol, natalizumab, vedolizumab, etrolizumab, ustekinumab, mirikizumab, briakinumab, ontamalimab, risankizumab, brazikumab, and guselkumab. This evidence concerns the gene TNF and inflammatory bowel disease.